Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Shares Issued (2017 - 2025)

Historic Shares Issued for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to $46000.0.

  • Seres Therapeutics' Shares Issued fell 6567.16% to $46000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $230000.0, marking a year-over-year decrease of 5277.21%. This contributed to the annual value of $487000.0 for FY2024, which is 7735.94% down from last year.
  • Latest data reveals that Seres Therapeutics reported Shares Issued of $46000.0 as of Q3 2025, which was down 6567.16% from $184000.0 recorded in Q1 2025.
  • Seres Therapeutics' Shares Issued's 5-year high stood at $99.1 million during Q3 2022, with a 5-year trough of -$3.3 million in Q4 2022.
  • In the last 5 years, Seres Therapeutics' Shares Issued had a median value of $353000.0 in 2024 and averaged $7.8 million.
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Shares Issued was 5685862.07% (2022), while the steepest drop was 205178.57% (2022).
  • Seres Therapeutics' Shares Issued (Quarter) stood at $168000.0 in 2021, then tumbled by 2051.79% to -$3.3 million in 2022, then soared by 128.12% to $922000.0 in 2023, then tumbled by 85.47% to $134000.0 in 2024, then tumbled by 65.67% to $46000.0 in 2025.
  • Its Shares Issued stands at $46000.0 for Q3 2025, versus $184000.0 for Q1 2025 and $134000.0 for Q3 2024.